John Guanjing Zhang’s Post

https://buff.ly/4cXCfSY SelSym, a pioneering startup, is addressing the challenge of platelet storage limitations. Due to their short lifespan, platelets cannot be stored for future use, despite a substantial number of donations. The innovative solution being developed by SelSym involves the utilization of soft artificial platelets to effectively control bleeding. This groundbreaking approach holds promise in revolutionizing the way bleeding is managed. #MedicalInnovation #BleedingControl

The #biotech entrepreneurial journey can be equal parts frustrating, exhilarating, and rewarding. In the early stages, it's essential to keep an eye on scalability and lean on partners who can help you reach your next milestone quickly and cost-effectively. Our customers attest that RoosterBio can be a powerful resource for #advancedtherapy startups by providing: ✅ Scalable and economical raw materials to take you from bench to clinic ✅ Technical guidance along the way to optimize your chance of success ✅ Expert-led services to advance your research quickly and efficiently with reduced overhead cost Learn more: https://lnkd.in/eMGMeNV3 #advancedtherapies #regenerativemedicine #gotomarket #biotechinnovation #startup

🔬 From Scientist to Entrepreneur: Key Insights Are you a scientist thinking about venturing into entrepreneurship? Prof. Thomas Baumert through BaseLaunch, shares valuable advice on making this transition. His tips cover crucial areas such as protecting intellectual property and engaging with investors. 👉 Read the full article for all nine essential tips: https://lnkd.in/eRKD89wv #Biotech #Entrepreneurship #Innovation #Startups #BaseLaunch

Join B2DG's upcoming event on 04/23/24 to learn how investors evaluate successful startup companies. Gain insights into key business issues faced by new ventures, from concept to market. Learn the skills and tools required to start a new venture and how to drive the commercialization of your product. The event will use Melanoma Diagnostic as an example of patented technology, product validation, and a successful exit. Don't miss out on this opportunity to understand the vocabulary of investors and the management team. Register now at https://lnkd.in/g92Ryfwd #startups #investors #newventures #entrepreneurship #commercialization

📢 CTAN invests over $800k in ICHOR Vascular! Central Texas Angel Network is thrilled to announce its substantial investment of over $800,000 in ICHOR Vascular Inc., a company revolutionizing peripheral clot removal. ICHOR's innovative solution for Peripheral Artery Disease (PAD) and Deep Vein Thrombosis (DVT) eliminates the need for traditional drug therapies and surgeries. Jean Cheever, a key CTAN Deal Team member, said, "ICHOR’s creation of a solution that has the potential to not only enhance patient outcomes but also drive down healthcare costs substantially.” Tim Blair, CEO of ICHOR Vascular, expressed gratitude, "This funding will expedite our efforts to bring our innovative solution to market...we need better tools for patients, and we need to address health economics that plague our health system." Stay tuned for more exciting updates from CTAN as we continue to support groundbreaking ventures! #AngelInvesting #HealthcareInnovation #MedicalTech #StartupFunding #AustinTX #Entrepreneurs #Startups Read the full press release:

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> In biotech's uneven recovery, 50 startups raised megarounds in first half of 2024: The list of nine-figure financings for private biotechs is starting to look like the scrolling receipts from CVS or Walgreens. If that pace continues, it could top the heydays of 2020 and 2021. In the first half of the year, at least 50 biotechs announced private financing rounds of $100 million or more, according to an Endpoints News tally. Investors sprinted out of the gate this year, announcing 21 megarounds by March 20. The pace accelerated in the second quarter as they mainly put their dollars toward companies already in the clinic, meaning a data readout or big de-risking event is on the horizon. About 15 of the 50 companies were not yet in the clinic at the time of a financing announcement. Most of the venture dollars are supporting research and testing of new medicines across today’s biggest biopharma fields: oncology, obesity, autoimmune and neuroscience. Beacon Therapeutics carried the momentum into the second half of the year. The pivotal-stage gene therapy maker announced a $170 million Series B on Wednesday. The two-month moving average of weekly venture capital volume is up 50% compared to a low in February, according to Tim Opler, an investment banker at Stifel who tracks the industry. “The venture market has been picking up in recent months,” he wrote in his weekly market report on June 16. “Nonetheless, venture funding is going more and more into ‘megarounds,’ and it is not easy for emerging companies lacking superstar management to raise capital.” One of the 50 companies to raise a megaround this year is immunology biotech Alumis, which has since gone public. Another megaround company — ADC maker ProfoundBio — was acquired by Genmab for $1.8 billion. Some of the biotechs on this list could likely entertain similar exits in the near future as the IPO market appears to warm up a little bit and pharma M&A appetite to favor private drug developers over public ones. #lucidquest #genetherapy #celltherapy

Lamark Biotech, a T-Angel startup is redefining the accessibility of modern medicine for under-developed areas. Most vaccines, especially for insulin, eye degeneration, and lung cancer need refrigeration and stability. Vaibhav Bhatia, CEO at Lamark Biotech talks about how the company has dedicated itself to making these medicines refrigerator-independent so that it can reach the deepest parts of the country! Watch Vaibhav talk about T-Hub's support at multiple levels from legality and due diligence to end-to-end assistance in being investment-ready! T-Hub is empowering founders and their startups. Watch here: https://bit.ly/49EMIAK #THubFounderTalks #InnovateWithThub #InnovationEcosystem

In the technology sector, the current landscape presents a tale of haves and have-nots. According to Hunt, there is available capital, but a significant portion of it remains locked up, hindering its flow to early startups through VCs. This situation has resulted in a scarcity of IPOs, indicating a challenging environment for emerging companies. Despite these challenges, there is optimism within ARM that the situation might improve. Hunt expresses hope that with the anticipated decrease in interest rates and other stabilizing factors, the gears will gradually begin to unlock, potentially easing the funding constraints faced by startups. #Technology #Startups #VentureCapital #IPOs #MarketTrends #OnTheMessa #CellAndGeneTherapy

Biotech Startups Aim High: Companies Seek $400M in IPOs Spotlight on: -Upstream Bio (UPB): Targeting $212.5M for respiratory treatments -CAMP4 Therapeutics (CAMP): Seeking $80M for genetic disease therapies -Ceribell │ AI-Powered Point-of-Care EEG (CBLL): Aiming for $107.2M with neurological monitoring tech Startups rush to capitalize on potential Fed rate cuts, despite looming election uncertainty. Expert: "Biotechs may want to capture current market momentum." #OBI4You https://lnkd.in/gSAeSF4u

Empowering the Next Wave of Unicorns: Startup Karnataka's KAN and ELEVATE Initiatives The Karnataka Acceleration Network (KAN) aims to support 302 growth-stage startups over the next three years through mentorship, market access, and funding, especially in areas beyond Bengaluru. KAN offers a structured pathway for startups looking to scale, making Karnataka an ideal launchpad for growth. KAN builds on the ELEVATE 2024 initiative, a seed fund program started in 2016. With Rs 224.06 crore committed, ELEVATE has supported 983 early-stage startups, making Karnataka the first state with such comprehensive startup support. This commitment has established Karnataka as a leader in fostering entrepreneurship. With Bengaluru home to 45 of India’s 112 unicorns, valued at $161 billion, KAN and ELEVATE aim to propel Karnataka into the global top three startup ecosystems. By addressing funding gaps and promoting scalability, these programs are a game-changer for emerging founders and Karnataka’s position as an innovation hub. Kudos to Karnataka govt.(Priyank M Kharge, CM Siddaramaiah, Dr. Ekroop Caur) for leading the way in India’s startup revolution! If you or someone you know could benefit from this funding, explore application details here- https://lnkd.in/gYGkfNFC #KarnatakaStartups #IndianEntrepreneurship #StartupEcosystem #Innovation